28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
BackgroundZervimesine (CT1812) is a first-in-class, brain-penetrant sigma-2 receptor ligand that prevents binding and displaces Aβ42 oligomers from receptors on neuronal synapses. 3 key findings →
Design: clinical trial Participants: 153 Evidence: high
Full summary, score breakdown and related studies → Original source
Mean percentage change in plasma p-tau217 in the SAMe group was an increase of 53.22 (standard deviation [SD] 159.19) compared to 25.34 (SD 94.83) in the placebo group (standardized mean difference 37.58, 95% confidence interval -32.61, 107.76; p = 0.288). 4 key findings →
Design: clinical trial Participants: 63 Evidence: high
Full summary, score breakdown and related studies → Original source
Between Aug 28, 2013, and Dec 21, 2015, we enrolled 3494 participants (3061 at high risk and 433 at low risk). 5 key findings →
Design: clinical trial Participants: 3,494 Evidence: high
Full summary, score breakdown and related studies → Original source
From May 13, 2015, to July 22, 2020, 185 participants with Down syndrome were assessed for eligibility and 160 (86%) were randomly assigned either memantine (n=81) or placebo (n=79). 5 key findings →
Design: clinical trial Participants: 81 Evidence: high
Full summary, score breakdown and related studies → Original source
EVOKE (ClinicalTrials.gov NCT04777396) and EVOKE+ (NCT04777409) tested whether oral semaglutide, the GLP-1 diabetes/weight-loss drug, could slow early Alzheimer's disease progression in a combined 3,808 participants over up to 156 weeks. 4 key findings →
Design: phase-3-trial Participants: 3,808 Evidence: null result
Full summary, score breakdown and related studies → Original source
A total of 210 participants were enrolled and 82% completed 26 weeks of treatment. 5 key findings →
Design: clinical trial Participants: 210 Evidence: high
Full summary, score breakdown and related studies → Original source
Between Dec 8, 2009, and Dec 23, 2011, we randomly allocated 278 patients to treatment: 133 to placebo and 145 to idalopirdine. 132 patients in the placebo group and 140 in the experimental group were included in the final analysis. 5 key findings →
Design: clinical trial Participants: 278 Evidence: high
Full summary, score breakdown and related studies → Original source
BackgroundPreclinical and clinical evidence suggest that low-dose cannabinoids could ameliorate Alzheimer's disease (AD) signs and symptoms. 3 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in Alzheimer's disease and schizophrenia. 3 key findings →
Design: clinical trial Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source
Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models. 3 key findings →
Design: phase-2-trial Participants: 204 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
Group 3 showed less decrease in the SIB score at 12 and 24 weeks compared with group 1 (P < 0.05). 5 key findings →
Design: clinical trial Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source
Gradual up-titration of dose significantly reduced ARIA-E risk while demonstrating comparable pharmacokinetics/pharmacodynamics compared to standard dosing. 5 key findings →
Design: phase-3-trial Participants: 843 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Between Aug 23, 2010, and Nov 25, 2014, 326 men were enrolled, of whom 163 were randomly assigned to radical retropubic prostatectomy and 163 to robot-assisted laparoscopic prostatectomy. 18 withdrew (12 assigned to radical retropubic prostatectomy and six assigned to robot-assisted laparoscopic prostatectomy); thus, 151 in the radical retropubic prostatectomy group proceeded to surgery and 157 in the robot-assisted laparoscopic prostatectomy group. 121 assigned to radical retropubic prostatectomy completed the 12 week questionnaire versus 131 assigned to robot-assisted laparoscopic prostatectomy. 5 key findings →
Design: clinical trial Participants: 14 Evidence: high
Full summary, score breakdown and related studies → Original source
In APOE4/4 homozygotes receiving 150mg BID tramiprosate, efficacy in the traditional Mild AD patients (MMSE 20-26) was higher than the overall group (MMSE 16-26) and efficacy in the Mild patients (MMSE 22-26) was highest. 5 key findings →
Design: clinical trial Participants: 147 Evidence: high
Full summary, score breakdown and related studies → Original source
No beneficial effects were observed in the dual primary outcome measures for the 2 IVIg doses tested. 5 key findings →
Design: clinical trial Participants: 390 Evidence: low
Full summary, score breakdown and related studies → Original source
A total of 1795 participants were enrolled (lecanemab:898; placebo:897). 5 key findings →
Design: clinical trial Participants: 1,795 Evidence: low
Full summary, score breakdown and related studies → Original source
This is the primary Phase 3 Clarity AD trial report for lecanemab. 3 key findings →
Design: phase-3-trial Participants: 1,795 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This is the pivotal Phase 3 trial for donanemab in 1,736 people with early symptomatic Alzheimer's. Donanemab slowed decline on a combined cognitive/functional scale (iADRS) by about 22-35% relative to placebo over 76 weeks, depending on tau levels at baseline. 3 key findings →
Design: phase-3-trial Participants: 1,736 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Exercise intensity did not differentially affect cognitive trajectory. 2 key findings →
Design: phase-3-trial Participants: 296 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of the 120 participants (mean age, 71.4 [SD, 8.6] years; 55% were female), 93 (77.5%) completed the trial. 1 key finding →
Design: phase-2-trial Participants: 120 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
The primary outcome was difference in the change in Neuropsychiatric Inventory apathy scores for oxytocin versus placebo periods in the per-protocol population after 6 weeks of treatment. 2 key findings →
Design: phase-2-trial Participants: 94 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
The Integrated Alzheimer's Disease (AD) Rating Scale (iADRS) is a composite tool that combines scores from the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and the AD Cooperative Study - instrumental Activities of Daily Living (ADCS-iADL). 2 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
This trial tested an antibody targeting tau tangles rather than amyloid plaques, in people with mild-to-moderate Alzheimer's. It slowed decline on one cognitive test by 42% compared with placebo, the first time an anti-tau antibody showed any cognitive benefit, but it did not help with daily-function scores, overall dementia staging (CDR-SB), or the MMSE, and it did not reduce tangle buildup seen on tau brain scans. 5 key findings →
Design: phase-2-trial Participants: 272 Evidence: preliminary
Full summary, score breakdown and related studies → Original source
No benefits were demonstrated for secondary clinical end points. 3 key findings →
Design: phase-2-trial Participants: 327 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
Benefit continued to accrue with ongoing lecanemab treatment through 36 months. 5 key findings →
Design: phase-3-trial Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →